Plenary Session | 09:00 - 12:00, July 18 Global Trends of Healthcare Innovation: Technology, Business Model, Regulatory and Policy
Global healthcare is continuing to evolve at an unstoppable pace, with once futuristic technologies such as Artificial Intelligence (AI), Big Data, CRISPR, Cell and Gene therapies, Regenerative Medicine, and CAR-T immunotherapies now increasingly a part of today's biomedical landscape. Innovation is also the hallmark of all-new business, financial and investment models that are driving and funding these breakthroughs and the companies built around them. To effectively regulate the ever-evolving healthcare advancement, governments and regulatory agencies must up their game to keep pace, providing better guidance and developing policies to help keep the innovations rolling while also safeguarding the public. Leading industry experts will share their insights on these and other important trends shaping our industry in the not-to-be-missed Plenary Session of BioBusiness Asia 2018.
Session Chair: >> Johnsee Lee, Chairman, Taiwan Bio Industry Organization
Speakers: >> Sir Richard Roberts, Nobel Laureate (Inviting) >> Reenita Das, Senior Partner & SVP, Transformation Health, Frost & Sullivan (Inviting) >> Joseph Damond, Senior Vice President, International Affairs, Biotechnology Innovation Organization (BIO) (Inviting) >> Miron Lila, Senior Vice President, CitiGroup (Inviting)
Session 1 | 14:00 - 16:00, July 18 New Technology Trends Impacting Biotechnology
Recent years have seen an explosion in the development and application of new technologies across the full spectrum of healthcare, including drug discovery and development, diagnostics, and healthcare delivery. Advances in Artificial Intelligence (AI) have the potential to accelerate our ability to discern patterns and trends in the reams of data generated in the drug development process and to use this information to accelerate drug discovery and clinical trials. New technology platforms, including genome editing, cell and gene modalities, and microbiome engineering, may enable step-change improvements in our ability to treat challenging diseases, create new diagnostics, and improve our fundamental understanding of biology. Digital technologies, including wearables, promise to achieve real-time patient monitoring, enhance drug compliance, and achieve preventative medicine. Headlined by Tim Lu, MIT professor and serial entrepreneur, this session will examine how such technologies are revolutionizing the biotechnology industry, and what's in store for the years ahead.
Speakers: >> Jeffrey Lu, Co-Founder & CEO, Engine Biosciences >> Jason Wang, Associate Professor of Pediatrics and Medicine, Stanford University. >> More coming soon...
Session 2 | 14:00 - 18:00, July 18 Safeguard the Success of Your Biologics Development Investment
Biologics continue to lead other drug types in new drug approvals and revenue, while bringing new hope to those with once incurable conditions. Developing biopharmaceuticals remains difficult and complex, however, with new entrants faced with formidable challenges from Day One, such as unforgiving and expensive manufacturing processes, difficulties in scale-up, and the constant threat of contamination, to name a few. Decisions around capacity, to utilize single-use or reusable tanks, to innovate or to develop biosimilars, are all critical to the success or failure of a biologics enterprise. Industry insider Judy Chou leads this session with insight and experience in such issues as SVP and Head of Biotech at Bayer, with discussions covering regulatory compliance, manufacturing tips and pitfalls, and clinical trial considerations.
Speakers: >> Wei-Shou Hu, Distinguished McKnight University Professor, University of Minnesota >> Kazem Kazempour, President and CEO, Amarex Clinical Research, LLC >> More coming soon...
Session 3 | 09:00 - 18:00, July 19 Realizing Intelligent Precision Medicine for Next-Generation Healthcare
Healthcare is rapidly moving from a “one size fits all” to a “precision medicine” paradigm, a recognition of the lack of efficacy of many existing drugs and driven by advances in drug targeting and delivery, imaging, diagnostics, and in particular Next Generation Sequencing (NGS), which has allowed for the ability to personalize treatments based on genomic characteristics of both patients and diseases. This session, co-organized by the Drug Commercialization Center (DCC) and the Medical Device Commercialization Center (MDCC), will examine the current and future state of precision medicine, with a focus on the impact brought about by new advances in AI and Big Data. With Taiwan well placed to participate in the further development of this global healthcare movement, join our panel of local and international experts as they delve deep into this exciting topic from both therapeutics, diagnostics and healthcare management aspects.
Session Chairs: >> Johnsee Lee, Chairman, Taiwan Bio Industry Organization >> Chung- Hsiun Wu, CEO, Development Center for Biotechnology (DCB)
Speakers: >> Fong-Chin Su, Deputy Minister, Ministry of Science and Technology, Taiwan / CEO, Biomedical Industrial Innovation Promotion (BIIP) (Inviting) >> Michael Chang, CEO, Synergies Intelligent Systems, Inc. >> Steven Rosen, VP of BD & Strategy, Elucida Oncology (Inviting) >> Xander Verbeek, Chief Innovation Officer, IKNL (Integraal Kankercentrum Nederland) (Inviting) >> David Hansen, CEO of Australia E-Health Research Centre, CSIRO (Inviting) >> More coming soon...
Session 4 | 09:00 - 18:00, July 19 Innovative Business Models Through Creative Investment
Investment powers the life science industry like never before. Organized by PricewaterhouseCoopers (PwC) Taiwan, join our panel of expert speakers from Taiwan and abroad as they examine investment and financial considerations critical to a biotech company's evolution from startup onward. Included in this all-day session will be a thorough examination from angel funding, VC investment to the IPO process from both private sector and government perspectives. With Gilead Sciences’ 2017 US$$11B purchase of Kite Pharma, Thermo Fischer’s US$7 B acquisition of Dutch group Patheon, and just recently with Celgene buying Juno Therapeutics for US$9 B, the panel will also take a close look at how accelerating M&A activity is providing an alternative investment exit strategy to the traditional IPO route while driving growth and industry consolidation across the board in the pharma, biotech and medical devices sectors.
Session Chairs: >> Jo Shen, Vice Chairman of Taiwan Bio Industry Organization >> Hong-Jen Chang, Chairman, Taiwan Research-based Biopharmaceutical Manufacturers Association ( TRPMA )
Speakers: >> Hongbo Lu, Partner, Lilly Asia Ventures >> Hingge Hsu, NEST.Bio (Inviting) >> Bin LI, CEO, Ally Bridge LB Healthcare Fund >> George Yeh, President, TLC Taiwan Liposome Company >> Li, Minghui, General Manager&Director, MasterLink Securities Corporation >> More coming soon...
Opportunities & Challenges of Cross-Strait Collaborations | 09:00 - 12:00, July 20 Stepping Up the Partnership and Catching Up the Business Opportunities in China
Objectives To provide a platform for the pharmaceutical industry leaders from Taiwan and China to discuss the challenges and explore the opportunities of cross-strait collaborations. The goal is, with joint forces, industries in Taiwan and China will be able to compete effectively and to take the leadership in the global pharmaceutical business.
Background The recent changes of regulatory guidelines in China and the booming new drug development activities as fueled by the capital market created by the “Biotech New Drug Law” in Taiwan, opportunities have risen for collaborations between Taiwanese and Chinese companies in drug development, manufacturing, marketing and distribution for regional as well as global market penetrations. With BioTaiwan being the largest annual gathering of pharmaceutical players in Taiwan, holding a symposium with participations of leaders from both sides would be a great way to initiate and enhance movement of collaborations as well as identifying the strategic goals more precisely.
Session Chair: >> Grace Yeh, President & CEO, PharmaEngien
Speakers: >> Joseph Cho, Managing Director, RDPAC >> Jen Chen, Chairman, Genovate Biotechnology >> Jinsheng Ren, Founder, Chairman of the Board and CEO, Simcere Pharmaceutical Group >> More coming soon...
Southeast Asia Opportunities Conference | 09:00 - 18:00, July 20 Exploring and Sharing New Opportunities Among ASEAN Countries
With the Taiwan government's "New Southbound Policy" put in place explicitly to encourage commercial activity between Taiwan and its Southeast Asian neighbors. With this in mind, the BioTaiwan Organizing Committee has decided to include on the program all-new full-day event on uncovering collaboration and business opportunities in this region; the Southeast Asia Opportunities Conference. The first half of the conference will focus in on a selection of SE Asian nations to examine the current state of the healthcare environment each, and identify strengths, needs and future opportunities followed by a panel discussion on ”finding common goals and mutual benefits among differences”. In the afternoon the conference will feature experts with insight on a variety of topics including investment, clinical trials, trade considerations, and on governmental policies in a selection of countries as they apply to the healthcare sector. Join us for the inaugural holding of what will surely be a highly informative conference, with excellent networking opportunities included.
Session Chair: >> Johnsee Lee, Chairman, Taiwan Bio Industry Organization
Speakers: >> Taiwan and ASEAN Government Officials >> Building ASEAN Drug Development Strategies – Philippine / Malaysia / Myanmar >> Songpon Deechongkit, Managing Director, Abinis Co., Ltd. Bangkok Thailand >> Iwan Koswara, Director, PT Harsen Laboratories (Indonesia) >> More coming soon...